<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04084951</url>
  </required_header>
  <id_info>
    <org_study_id>SQZ-PBMC-HPV-101</org_study_id>
    <nct_id>NCT04084951</nct_id>
  </id_info>
  <brief_title>Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SQZ Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SQZ Biotechnologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic&#xD;
      effects, antitumor activity, and pharmacodynamics of SQZ-PBMC-HPV as monotherapy and in&#xD;
      combination with atezolizumab or other immune checkpoint inhibitors in HLA-A*02+ patients&#xD;
      with recurrent, locally advanced or metastatic human papillomavirus strain 16 positive&#xD;
      (HPV16+) solid tumors. The study includes patients with anal, rectal, cervical, head and&#xD;
      neck, penile, vulvar, or vaginal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE version 5.0</measure>
    <time_frame>Up to 1 year after LPFV (Last Patient, First Visit)</time_frame>
    <description>For SQZ-PBMC-HPV as a single agent and in combination with immune checkpoint inhibitors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 dose (RP2D)</measure>
    <time_frame>Up to 1 year after LPFV</time_frame>
    <description>RP2D of SQZ-PBMC-HPV as a single agent and in combination with immune checkpoint inhibitors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antitumor activity (Part 3 only)</measure>
    <time_frame>Up to 1 year after LPFV</time_frame>
    <description>Tumor assessments using RECIST 1.1 of SQZ PBMC-HPV monotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity (Parts 1 and 2)</measure>
    <time_frame>Up to 1 year after LPFV</time_frame>
    <description>Tumor assessments using RECIST 1.1 of SQZ PBMC-HPV monotherapy and in combination with immune checkpoint inhibitors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manufacturing feasibility (Part 1 only)</measure>
    <time_frame>Up to 3 months after LPFV</time_frame>
    <description>Individual patient batch yields</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with change in blood cytokine levels</measure>
    <time_frame>Up to 1 year after LPFV</time_frame>
    <description>SQZ-PBMC-HPV as a single agent and in combination with immune checkpoint inhibitors</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with development of endogenous immune responses as assessed by functional assay in CD8 T cells</measure>
    <time_frame>Up to 1 year after LPFV</time_frame>
    <description>Immunogenic effects on peripheral blood cells of SQZ-PBMC-HPV as a single agent and in combination with immune checkpoint inhibitors</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Adult Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Part 1 Monotherapy Dose Escalation Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1, SQZ-PBMC-HPV as a monotherapy is administered every 3 weeks for up to a year. There are at least 3 groups (&quot;Cohorts&quot;) in this Phase as follows:&#xD;
Cohort 1: low dose SQZ-PBMC-HPV&#xD;
Cohort 2: high dose SQZ-PBMC-HPV&#xD;
Cohort 3: high dose SQZ-PBMC-HPV double-priming</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Combination Safety Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 2, SQZ-PBMC-HPV in combination with immune checkpoint inhibitors (1) atezolizumab, (2) ipilimumab, (3) nivolumab, or (4) nivolumab and ipilimumab, is administered every 3 weeks for up to a year except atezolizumab may be given up to 2 years; and ipilimumab will be administered four times (in a timeframe less than a year) if safety allows. There are 4 groups (&quot;Cohorts&quot;) in this Phase as follows:&#xD;
Cohort 4: SQZ-PBMC-HPV RP2D (Recommended Phase 2 Dose) plus atezolizumab&#xD;
Cohort 5: SQZ-PBMC-HPV RP2D plus ipilimumab&#xD;
Cohort 6: SQZ-PBMC-HPV RP2D plus nivolumab&#xD;
Cohort 7: SQZ-PBMC-HPV RP2D plus nivolumab and ipilimumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 Monotherapy Dose Expansion Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 3, SQZ-PBMC-HPV is administered at the RP2D to patients enrolled in HPV16+ cancer-type specific cohorts. There are 4 groups (&quot;Cohorts&quot;) in this Phase as follows:&#xD;
Cohort 8: SQZ-PBMC-HPV RP2D in HPV16+ head and neck cancer patients&#xD;
Cohort 9: SQZ-PBMC-HPV RP2D in HPV16+ cervical cancer patients&#xD;
Cohort 10: SQZ-PBMC-HPV RP2D in HPV16+ anal cancer patients&#xD;
Cohort 11: SQZ-PBMC-HPV RP2D in other HPV16+ cancer patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SQZ-PBMC-HPV</intervention_name>
    <description>antigen presenting cell therapy; therapeutic vaccine consisting of peripheral blood mononuclear cells (PBMCs) manufactured with immunogenic epitopes of HPV16</description>
    <arm_group_label>Part 1 Monotherapy Dose Escalation Phase</arm_group_label>
    <arm_group_label>Part 2 Combination Safety Phase</arm_group_label>
    <arm_group_label>Part 3 Monotherapy Dose Expansion Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>programmed cell death ligand 1 (PD-L1) blocking antibody</description>
    <arm_group_label>Part 2 Combination Safety Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody</description>
    <arm_group_label>Part 2 Combination Safety Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>programmed cell death 1 (PD-1) blocking antibody</description>
    <arm_group_label>Part 2 Combination Safety Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients â‰¥18 years of age who are HLA-A*02+&#xD;
&#xD;
          -  Histologically confirmed incurable or metastatic solid tumors that are HPV16+&#xD;
&#xD;
          -  Cancer must have progressed after at least 1 available standard therapy for incurable&#xD;
             disease, or the patient is intolerant to or refuses standard therapy(ies) or has a&#xD;
             tumor for which no standard therapy(ies) exist&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1&#xD;
&#xD;
          -  At least 1 measurable lesion according to RECIST 1.1&#xD;
&#xD;
          -  Must have a lesion that can be biopsied with acceptable clinical risk and agree to&#xD;
             have a fresh biopsy at Baseline and on Cycle 2 Day 8 (+/- 3 days)&#xD;
&#xD;
          -  Patients must agree to venous access for the leukapheresis and be willing to have a&#xD;
             central line inserted if venous access is an issue&#xD;
&#xD;
          -  Adequate organ function and bone marrow reserve performed within 14 days prior to the&#xD;
             leukapheresis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with anticancer therapy, including investigational therapy, within 2 weeks&#xD;
             prior to leukapheresis. For prior therapies with a half-life longer than 3 days,&#xD;
             discontinuation of the therapy must have occurred at least 28 days prior to&#xD;
             leukapheresis&#xD;
&#xD;
          -  Systemic treatment with either corticosteroids (&gt;10 mg of prednisone or the equivalent&#xD;
             per day) or other immunosuppressive medications within 14 days prior to leukapheresis&#xD;
&#xD;
          -  Patients treated with non-corticosteroid based immunosuppressive agents within the&#xD;
             last 6 months may not be eligible and should be discussed with the Sponsor&#xD;
&#xD;
          -  Patients with active, known, or suspected autoimmune disease may not be eligible and&#xD;
             should be discussed with the Sponsor&#xD;
&#xD;
          -  Patients with &gt;Grade 1 AEs related to previous treatment with anticancer or&#xD;
             investigational therapy that do not resolve at least 2 weeks prior to leukapheresis,&#xD;
             except Grade 2 alopecia&#xD;
&#xD;
          -  Known active hepatitis B or hepatitis C, or active mycobacterium tuberculosis&#xD;
             infection&#xD;
&#xD;
          -  History of any Grade 4 immune-related AE (irAE) from prior immunotherapy&#xD;
&#xD;
          -  Has known active central nervous system metastases&#xD;
&#xD;
          -  History of interstitial lung disease requiring steroids&#xD;
&#xD;
          -  Significant acute or chronic illness&#xD;
&#xD;
          -  Major surgery within 2 weeks of leukapheresis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ricardo F. Zwirtes, MD</last_name>
    <phone>203-506-7253</phone>
    <email>PBMC-HPV-101@sqzbiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer</last_name>
      <phone>480-323-1364</phone>
      <email>clinicaltrials@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Michael S Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari Kayser, BSN, RN,CCRP</last_name>
      <phone>310-967-0694</phone>
      <email>kari.kayser@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Monica Mita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Anschutz Cancer Pavillion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Nguyen</last_name>
      <phone>720-848-4394</phone>
      <email>ana.nguyen@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Antonio Jimeno, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Roesgen</last_name>
      <phone>913-945-8679</phone>
      <email>jroesgen@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Joaquina Baranda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Valles, RN</last_name>
      <email>bvalles@partners.org</email>
    </contact>
    <investigator>
      <last_name>Jong Chul Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-6840</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Nielsen</last_name>
      <email>pnielsen@nebraskamed.com</email>
    </contact>
    <investigator>
      <last_name>Kerry Rodabaugh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Office</last_name>
      <phone>503-215-2614</phone>
      <email>canrsrchstudies@providence.org</email>
    </contact>
    <investigator>
      <last_name>Matthew H Taylor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Information Program</last_name>
      <phone>800-811-8480</phone>
      <email>CIP@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Wade Thomas Iams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>New Patient Referral Centre (NPRC)</last_name>
      <phone>416-946-4575</phone>
    </contact>
    <investigator>
      <last_name>Neesha Dhani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 1, 2019</study_first_submitted>
  <study_first_submitted_qc>September 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumors cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>locally advanced</keyword>
  <keyword>cancer</keyword>
  <keyword>cervical</keyword>
  <keyword>head and neck</keyword>
  <keyword>anal</keyword>
  <keyword>penile</keyword>
  <keyword>SQZ-PBMC-HPV</keyword>
  <keyword>atezolizumab</keyword>
  <keyword>HPV16</keyword>
  <keyword>APC</keyword>
  <keyword>cell therapy</keyword>
  <keyword>ipilimumab</keyword>
  <keyword>nivolumab</keyword>
  <keyword>checkpoint inhibitors</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>solid tumor</keyword>
  <keyword>HLA-A*02</keyword>
  <keyword>therapeutic vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

